FDMT

4D Molecular Therapeutics Inc

12.28

Nov 04 • 3:59 PM ET +0.33 (2.76%)

12.28

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: RGNX OCUL EYPT KOD OCGN REGN QURE SANA KRYS ABBV

| Held by: VTI XBI IWM VXF IWN IBB VTWO DFAS KOMP SCHA

Scroll to Statements

Index	RUT
Market Cap	678.40M
Enterprise Value	356.29M
Income	-179.18M
Sales	92.01M
Book/sh	7.38
Cash/sh	6.54
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	196
IPO	Dec 11, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	7.37
P/B	1.66
P/C	1.88
P/FCF	-
EV/EBITDA	-
EV/Sales	3.87
Quick Ratio	8.03
Current Ratio	8.03
Debt/Eq	0.10
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-2.72
EPS next Y	-4.09
EPS next Q	-1.05
EPS this Y	-71.53%
EPS next Y	1.37%
EPS next 5Y	-15.85%
EPS past 3/5Y	10.05% -2.62%
Sales past 3/5Y	200.86% 44.32%
EPS Y/Y TTM	26.59%
Sales Y/Y TTM	278712.12%
EPS Q/Q	-6.20%
Sales Q/Q	25106.67%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-2.29% 4.45%

Insider Own	8.62%
Insider Trans	-8.05%
Inst Own	99.88%
Inst Trans	16.85%
ROA	-37.09%
ROE	-43.25%
ROIC	-40.58%
Gross Margin	91.17%
Oper. Margin	-214.24%
Profit Margin	-194.74%
SMA20	0.06%
SMA50	-8.96%
SMA200	12.28%
Trades

Shs Outstand	55.21M
Shs Float	50.48M
Short Float	22.84%
Short Ratio	11.45
Short Interest	11.53M
52W High	16.93 -27.47%
52W Low	6.96 76.44%
Volatility	7.69% 7.63%
ATR (14)	0.94
RSI (14)	47.98
Beta	2.91
Rel Volume	0.76
Avg Volume	1.01M
Volume	764,484

Perf Week	-5.03%
Perf Month	-2.23%
Perf Quarter	16.40%
Perf Half Y	17.85%
Perf YTD	63.73%
Perf Year	14.23%
Perf 3Y	5.86%
Perf 5Y	-49.92%
Perf 10Y	-
Recom	1.25
Target Price	28.09
Prev Close	11.95
Price	12.28
Change %	2.76%

Consensus

Strong Buy

Avg. Price Target

$28.09

Implied Upside

+128.7%

Analysts12incl. previous ratings

Rating Distribution9 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 14, 2026	Upgrade	CCantor Fitzgerald	Neutral → Overweight	$20	+62.9%
Jul 31, 2026	Initiated	RB. Riley Securities	Buy	$37	+201.3%
Jan 28, 2026	Resumed	BBarclays	Overweight	$33	+168.7%
Nov 07, 2025	Upgrade	MMorgan Stanley	Underweight → Equal-Weight
Jan 13, 2025	Downgrade	BBMO Capital Markets	Outperform → Market Perform	$40 → $15	+22.1%
Nov 21, 2024	Initiated	MMorgan Stanley	Underweight	$8	-34.9%
Sep 23, 2024	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Apr 15, 2024	Initiated	BBarclays	Overweight	$459	+3,637.8%
Apr 15, 2024	Initiated	BBarclays	Overweight	$45	+266.4%
Feb 07, 2024	Resumed	GGoldman	Buy	$81	+559.6%
Oct 26, 2023	Initiated	RRBC Capital Mkts	Outperform	$25	+103.6%
Oct 24, 2023	Initiated	CCantor Fitzgerald	Overweight	$32	+160.6%
Oct 18, 2023	Upgrade	LLeerink Partners	Market Perform → Outperform	$24	+95.4%
Jul 05, 2023	Initiated	CChardan Capital Markets	Buy	$30	+144.3%
Jan 30, 2023	Initiated	BBMO Capital Markets	Outperform	$50	+307.2%
Nov 18, 2022	Initiated	HH.C. Wainwright	Buy	$36	+193.2%
Nov 15, 2022	Upgrade	GGoldman	Neutral → Buy	$12 → $68	+453.7%
Aug 12, 2022	Downgrade	SSVB Leerink	Outperform → Mkt Perform	$12	-2.3%
Jun 22, 2022	Initiated	JJefferies	Buy	$22	+79.2%
Jan 04, 2022	Initiated	SSVB Leerink	Outperform	$30	+144.3%

Nov-03-26 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.10%
Oct-16-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) -5.67%
Oct-05-26 08:00AM	4DMT to Host Investor Day on October 21, 2026 (GlobeNewswire) -5.49%
Sep-29-26 05:24PM	This is the top biotech stock pick from B Riley Securities (Investing.com)
Sep-28-26 01:15PM	OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs (Stocktwits)
08:00AM	Loading…
08:00AM	4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME (GlobeNewswire)
Sep-11-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Aug-25-26 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-26 07:51PM	OCUL, FDMT Stock Clock Best Day In Weeks After EyePoints Trial Setback Heres Why (Stocktwits) +19.32%
Aug-14-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Aug-13-26 04:05PM	4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Jul-31-26 09:46AM	Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls (The Fly)
Jul-29-26 03:22PM	10 Stock Picks to Celebrate 45 Years of Schaeffer's (Schaeffer's Research)
Jul-18-26 03:15PM	4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population (GlobeNewswire)
Jul-17-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
04:05PM	Loading…
Jun-30-26 04:05PM	4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists (GlobeNewswire)
Jun-29-26 08:00AM	4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital (GlobeNewswire) +11.03%
08:00AM	4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD (GlobeNewswire)
Jun-12-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
May-27-26 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) -6.73% -8.58%
May-07-26 04:05PM	4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
May-04-26 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-17-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Mar-18-26 04:05PM	4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Mar-16-26 08:00AM	4DMT to Participate in Upcoming Investor Meetings (GlobeNewswire)
Feb-28-26 02:21AM	Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? (Insider Monkey)
Feb-19-26 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-13-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Feb-09-26 08:00AM	4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD (GlobeNewswire)
09:53AM	Loading…
Feb-02-26 09:53AM	Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) (Insider Monkey)
Jan-17-26 08:00AM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Jan-07-26 08:00AM	4DMT Provides Company Update and Anticipated Development Milestones for 2026 (GlobeNewswire) +8.07%
Dec-27-25 07:43AM	Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely (Insider Monkey)
Dec-17-25 07:00AM	4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease (GlobeNewswire) -20.05%
Dec-12-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Dec-08-25 08:00AM	4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-20-25 08:00AM	4DMT to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-17-25 06:00AM	4DMT Appoints Kristian Humer as Chief Financial Officer (GlobeNewswire)
Nov-14-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Nov-10-25 09:15AM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Nov-06-25 04:05PM	4DMT to Participate in Jefferies 2025 London Healthcare Conference (GlobeNewswire)
06:23AM	4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:00AM	4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years (GlobeNewswire)
Oct-30-25 11:02PM	4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific (GlobeNewswire)
Oct-26-25 06:05AM	4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development (Insider Monkey)
Oct-17-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +14.53%
09:55AM	Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High? (Zacks)
Oct-14-25 08:00AM	4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Oct-13-25 08:00AM	4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation (GlobeNewswire) +8.65%
Sep-12-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Sep-11-25 12:45PM	SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag (Zacks)
Sep-05-25 03:12AM	Jim Cramer on 4D Molecular Therapeutics: "This is a Pure Spec" (Insider Monkey) +9.98%
Sep-02-25 08:20PM	Lightning Round: Now is time to take a little off the table with Applovin, says Jim Cramer (CNBC TV) +5.37%
08:00AM	4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness (GlobeNewswire)
Aug-25-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Aug-11-25 06:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +11.21%
08:00AM	4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Aug-06-25 08:00AM	4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.29%
Jul-31-25 04:05PM	4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update (GlobeNewswire) +42.67%
Jul-28-25 07:21AM	AAV for the Hereditary Retinal Diseases Market Competitive Landscape Report 2025 \| Novartis, MeiraGTx, 4D Molecular Therapeutics, and Beacon Therapeutics Lead the Charge in Innovative Therapies (GlobeNewswire)
Jul-24-25 08:00AM	4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists (GlobeNewswire)
Jul-21-25 08:00AM	BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer (Business Wire)
Jul-11-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Jul-02-25 04:05PM	4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution (GlobeNewswire)
May-28-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-16-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +7.50% +10.47%
May-08-25 05:50PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
May-05-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-02-25 06:51AM	FDA awards RMAT status to 4DMT diabetic macular oedema therapy (Pharmaceutical Technology) +9.30%
May-01-25 08:00AM	4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME (GlobeNewswire)
Apr-11-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +5.70%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -7.43%
Mar-27-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-10-25 08:00AM	4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD (GlobeNewswire)
Mar-04-25 08:05AM	4D Molecular price target lowered to $35 from $39 at RBC Capital (TipRanks)
Feb-28-25 04:05PM	4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire) -8.61%
Feb-19-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-08-25 02:30PM	4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program (GlobeNewswire)
Jan-29-25 08:00AM	4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population (GlobeNewswire) +7.53%
Jan-10-25 08:00AM	4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD and DME and 4D-710 in CF and Extends Cash Runway (GlobeNewswire) -5.48%
08:00AM	4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway (GlobeNewswire)
08:00AM	4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path (GlobeNewswire)
Dec-16-24 08:00AM	4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS (GlobeNewswire)
Nov-26-24 06:51AM	4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
Nov-14-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV (GlobeNewswire)
Nov-13-24 05:20PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Sep-25-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-23-24 08:00AM	4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-19-24 02:34PM	4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate (Benzinga) -19.74%
10:30AM	4D Molecular data bode well for eye gene therapy, but shares fall (BioPharma Dive)
Sep-18-24 04:05PM	4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day (GlobeNewswire)
Sep-05-24 08:00AM	4DMT Announces Presentations at Upcoming Retina Conferences (GlobeNewswire)
Sep-03-24 08:00AM	4DMT to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-27-24 08:00AM	4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 (GlobeNewswire)
Aug-23-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bizily Scott	Chief Legal Officer	Oct 16 '26	Option Exercise	4.14	1,635	6,769	10,252	Oct 20 04:56 PM
Bizily Scott	Chief Legal Officer	Oct 16 '26	Sale	12.84	1,635	20,993	8,617	Oct 20 04:56 PM
Kirn David	See Remarks	Oct 05 '26	Sale	12.92	58,333	753,937	709,153	Oct 07 05:11 PM
David Kirn	Officer	Oct 05 '26	Proposed Sale	12.92	58,333	753,662		Oct 05 06:23 PM
Bizily Scott	Chief Legal Officer	Sep 16 '26	Option Exercise	4.14	1,635	6,769	10,252	Sep 22 06:43 PM
Bizily Scott	Chief Legal Officer	Sep 16 '26	Sale	13.65	1,635	22,318	8,617	Sep 22 06:43 PM
Kirn David	See Remarks	Sep 14 '26	Sale	13.90	58,333	811,004	767,486	Sep 16 05:13 PM
David Kirn	Officer	Sep 14 '26	Proposed Sale	13.76	58,333	802,662		Sep 14 06:00 PM
Bizily Scott	Chief Legal Officer	Sep 01 '26	Option Exercise	6.49	584	3,790	9,201	Sep 03 06:55 PM
Bizily Scott	Chief Legal Officer	Sep 01 '26	Sale	14.00	584	8,176	8,617	Sep 03 06:55 PM
Kirn David	See Remarks	Aug 19 '26	Option Exercise	4.14	50,000	207,000	894,895	Aug 21 04:06 PM
Kirn David	See Remarks	Aug 19 '26	Sale	15.75	69,076	1,088,273	825,819	Aug 21 04:06 PM
David Kirn	Officer	Aug 19 '26	Proposed Sale	16.76	69,076	1,157,714		Aug 19 06:28 PM
Bizily Scott	Chief Legal Officer	Aug 13 '26	Option Exercise	4.14	1,635	6,769	10,252	Aug 17 05:34 PM
Bizily Scott	Chief Legal Officer	Aug 17 '26	Option Exercise	4.14	1,635	6,769	10,252	Aug 17 05:34 PM
Bizily Scott	Chief Legal Officer	Aug 17 '26	Sale	12.20	1,635	19,947	8,617	Aug 17 05:34 PM
Bizily Scott	Chief Legal Officer	Aug 13 '26	Sale	12.00	1,635	19,620	8,617	Aug 17 05:34 PM
SCOTT BIZILY	Officer	Aug 17 '26	Proposed Sale	12.19	6,540	79,723		Aug 17 04:46 PM
SCOTT BIZILY	Officer	Aug 13 '26	Proposed Sale	11.87	1,635	19,407		Aug 13 04:33 PM
Kirn David	See Remarks	Aug 04 '26	Sale	10.23	26,842	274,596	844,895	Aug 05 04:10 PM
David Kirn	Officer	Aug 04 '26	Proposed Sale	10.26	26,842	275,399		Aug 04 06:08 PM
Kirn David	See Remarks	Aug 03 '26	Sale	10.05	12,415	124,722	871,737	Aug 04 04:45 PM
David Kirn	Officer	Aug 03 '26	Proposed Sale	10.09	12,415	125,267		Aug 03 05:29 PM
Kirn David	See Remarks	Jul 09 '26	Sale	12.87	42,608	548,177	899,877	Jul 14 05:04 PM
Kirn David	See Remarks	Jul 10 '26	Sale	12.03	15,725	189,233	884,152	Jul 14 05:04 PM
David Kirn	Officer	Jul 10 '26	Proposed Sale	12.31	15,725	193,575		Jul 10 04:54 PM
David Kirn	Officer	Jul 09 '26	Proposed Sale	12.89	42,608	549,217		Jul 09 05:21 PM
SCOTT BIZILY	Officer	Jun 30 '26	Proposed Sale	12.88	6,566	84,570		Jun 30 04:38 PM
Bizily Scott	Chief Legal Officer	Jun 23 '26	Option Exercise	4.14	9,810	40,613	18,427	Jun 25 04:38 PM
Bizily Scott	Chief Legal Officer	Jun 23 '26	Sale	12.00	9,810	117,720	8,617	Jun 25 04:38 PM
SCOTT BIZILY	Officer	Jun 23 '26	Proposed Sale	10.42	9,810	102,220		Jun 23 04:29 PM
Kirn David	See Remarks	Jun 22 '26	Sale	10.47	114,746	1,200,851	942,485	Jun 23 04:19 PM
David Kirn	Officer	Jun 22 '26	Proposed Sale	10.42	114,746	1,195,653		Jun 22 05:58 PM
Kirn David	See Remarks	Jun 01 '26	Sale	10.02	1,922	19,258	1,057,231	Jun 02 04:48 PM
David Kirn	Officer	Jun 01 '26	Proposed Sale	9.71	1,922	18,663		Jun 01 05:40 PM
Gupta Ashoo	VP, Finance and Controller	Mar 20 '26	Sale	8.61	390	3,358	46,914	Mar 24 06:30 PM
Gupta Ashoo	VP, Finance and Controller	Dec 20 '25	Sale	8.68	389	3,377	46,218	Dec 23 09:05 PM
Bizily Scott	Chief Legal Officer	Dec 16 '25	Option Exercise	4.14	1,635	6,769	5,229	Dec 19 04:10 PM
Bizily Scott	Chief Legal Officer	Dec 16 '25	Sale	10.90	1,635	17,822	3,594	Dec 19 04:10 PM
THEUER CHARLES	Director	Dec 12 '25	Option Exercise	1.14	9,333	10,640	41,684	Dec 16 04:35 PM
SCOTT BIZILY	Officer	Dec 16 '25	Proposed Sale	10.95	1,635	17,903		Dec 16 04:33 PM
Bizily Scott	Chief Legal Officer	Nov 17 '25	Option Exercise	4.14	1,635	6,769	5,229	Nov 19 09:53 PM
Bizily Scott	Chief Legal Officer	Nov 17 '25	Sale	10.59	1,635	17,315	3,594	Nov 19 09:53 PM
SCOTT BIZILY	Officer	Nov 17 '25	Proposed Sale	10.79	1,635	17,642		Nov 17 04:33 PM

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. The company combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine creates a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Executive ChairmanDr. John F. Milligan Ph.D.

Co-FounderDr. David H. Kirn M.D.

CFO and Principal Financial & Accounting OfficerMr. Kristian Humer M.B.A.

Chief Technical AdvisorDr. Fariborz Kamal Ph.D.

Co-Founder & Chief of StaffMs. Theresa Janke

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FDMT

4D Molecular Therapeutics Inc

Upgrade your Finviz experience